Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0871 • ACR Convergence 2025
The gut microbiome shapes MTX pharmacology and is linked to treatment outcomes
Vanya Sofia Villa Soto¹, Diego Orellana², Erin Reilly³, Chloe Heath², Alexandra Degraeve², Mohana Mukherjee², darren Dumlao², Rebecca Blank⁴, steven Yu², Noah Perlmutter², Judith Ashouri², Jose Scher⁵, andrew Patterson³, Peter Turnbaugh² and Renuka Nayak⁶, ¹University of California, San Francisco, San Francics, CA, ²University of California, San Francisco, San Francisco, CA, ³Pennsylvania State University, University Park, PA, ⁴NYU Langone Health, New York, NY, ⁵New York University School of Medicine, New York, NY, ⁶University of California, San Francisco (UCSF), San Francisco, CA
Background/Purpose: Despite advances in targeted therapeutics, methotrexate (MTX) remains the first-line therapy in the treatment of rheumatoid arthritis (RA) and other inflammatory arthritides. However, more…
Abstract Number: 0799 • ACR Convergence 2025
Citrullination of neutrophil serine proteases enhances proteolytic activity, stability and autoantigenicity in Rheumatoid Arthritis
Mario Navarrete Lagos, Ramiza Zaman, Jun Kim, Jeba Atkia Maisha, Hani El-Gabalawy and Liam O'Neil, University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: In Rheumatoid Arthritis (RA), autoantibodies develop against endogenous proteins containing the amino acid citrulline, which results from a post-translational modification of arginine catalyzed by…
Abstract Number: 0497 • ACR Convergence 2025
Drug Survival and Discontinuation Reasons of Eight Biological Disease-Modifying Antirheumatic Drugs in 1,182 Patients with Rheumatoid Arthritis: A Retrospective Study Using the Niigata Orthopedic Rheumatoid Arthritis Database (NOSRAD)
Nariaki Hao and Naoki Kondo, Division of Orthopedic Surgery, Niigata University Medical and Dental General Hospital, Niigata, Japan
Background/Purpose: To retrospectively evaluate drug survival and reasons for discontinuation of eight biological disease-modifying antirheumatic drugs (bDMARDs) in rheumatoid arthritis (RA) patients using the Niigata…
Abstract Number: 0478 • ACR Convergence 2025
Racial and Ethnic Disparities in DMARD Use and in Medicare Part B-Covered Options Among Medicare Beneficiaries with Late-Onset Rheumatoid Arthritis
ashkan ara¹, John FitzGerald² and Susan Ettner², ¹UCLA Health, Los Angeles, CA, ²UCLA, Los Angeles, CA
Background/Purpose: Biologic and targeted synthetic DMARDs can substantially improve the quality of life for Medicare beneficiaries with rheumatoid arthritis (RA). However, racial and ethnic disparities…
Abstract Number: 0462 • ACR Convergence 2025
Does Biological Sex Affect Mortality in Frail Patients with Rheumatoid Arthritis?
Sayuli Bhide¹, Hannah Brubeck², Punyasha Roul³, Aaron Baraff², Bryant England⁴, Nadine El-Ayache¹, Grant Cannon⁵, Namrata Singh⁶, Gary Kunkel⁷, Ted Mikuls⁴, Dolores Shoback⁸, Kaleb Michaud⁴, Patti Katz⁹, Jose Garcia¹⁰, Ariela Orkaby¹¹, Joshua Baker¹² and Katherine Wysham¹³, ¹University of Washington, Seattle, WA, ²VA Puget Sound Health Care System, Seattle, WA, ³UNMC, Omaha, NE, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁶University of Washington, Bellevue, WA, ⁷University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁸San Francisco VA Medical Center & University of California San Francisco, San Francisco, CA, ⁹UCSF, San Rafael, CA, ¹⁰VA Puget Sound Health Care System, VA GRECC, and University of Washington, Seattle, WA, ¹¹Veterans Affairs Boston Healthcare System & Brigham and Women’s Hospital, Boston, MA, ¹²University of Pennsylvania, Philadelphia, PA, ¹³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA
Background/Purpose: Frailty predicts mortality in RA. In the general population, males have a higher risk of death than females despite lower levels of frailty.1 We…
Abstract Number: 0445 • ACR Convergence 2025
GLP-1 Receptor Agonists Reduce Mortality and Cardiovascular Events in Patients with Rheumatoid Arthritis
Giorgos Loizidis and Ross summer, Thomas Jefferson University, Philadelphia, PA
Background/Purpose: Obesity significantly increases cardiovascular morbidity and mortality in rheumatoid arthritis (RA), yet effective strategies for managing obesity-related risks in this population remain limited. Glucagon-like…
Abstract Number: 0379 • ACR Convergence 2025
Do Rheumatoid Arthritis Patients have Residual Fatigue Without Swollen Joints and Laboratory Inflammation? A Multicenter Study
Rosa Maria Morlà Novell¹, Enrique González-Dávila², Beatriz Frade Sosa³, Maria López-Lasanta⁴, Noemí Busquets Pérez⁵, Marta Valls Roc⁶, Meritxell Sallés Lizarzáburu⁷, Georgina Salvador Alarcón⁸, Virginia Ruiz-Esquide⁹, Lola Tobalina Mastre¹⁰, José Gomez-Puerta¹¹ and Raimon Sanmartí⁹, ¹Hospital Clínic de Barcelona, Barcelona, Spain, ²Departamento de Matemáticas. Universidad de La Laguna, Tenerife, Spain, ³Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ⁴Hospital Universitari Vall d´Hebron, Barcelona, Spain, ⁵Hospital de Granollers, Granollers, Spain, ⁶Hospital Universitari Dr Trueta, Girona, Sudan, ⁷Xarxa Sanitària Althaia Manresa, Manresa, Spain, ⁸Hospital Universitari Mùtua Terrassa, Terrassa, Spain, ⁹Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain, ¹⁰IDIBAPS. Hospital Clinic de Barcelona, Barcelona, ¹¹Rheumatology Department, Hospital Clinic, Barcelona, Spain, Barcelona, Spain
Background/Purpose: Residual fatigue highlights an unmet prevalent1 need in rheumatoid arthritis (RA) patients despite achieving remission of disease activity according to activity indices (DAS28).We examine…
Abstract Number: 0215 • ACR Convergence 2025
Impact of Global Review on Comorbidity Management in Inflammatory Arthritis Patients
Alexandra Kobza¹, Camille Bourgeois², Olivier Fogel³, Maxime Dougados⁴ and Anna Molto⁵, ¹University of Calgary, North Vancouver, BC, Canada, ²Hospital general universitario Gregorio Marañon, Madrid, Madrid, Spain, ³AP-HP, Paris, France, ⁴Department of Medicine, Hopital Cochin, Universite de Paris, Paris, France, ⁵Assistance Publique Hôpitauxde Paris, Paris, France
Background/Purpose: Patients with inflammatory arthritis (IA), including rheumatoid arthritis (RA) and spondyloarthritis (SpA), face elevated risk for comorbidities that complicate disease management. Although rheumatology societies…
Abstract Number: 0147 • ACR Convergence 2025
Rheumatoid Arthritis prevalence estimation in France using care pathways in the National Health Data System: opportunities and limitations – PREST study
cécile gaujoux-viala¹, adeline Ruyssen-Witrand², Laurent arnaud³, clélia Bignon-Favary⁴, Lauren Inchboard⁴ and Bruno Fautrel⁵, ¹Department of Rheumatology - CHU Nîmes, IDESP UM¹³¹⁸  INSERM – Univ. Montpellier, Nîmes, France, Nîmes, France, ²Department of Rheumatology, C.H.U. de Toulouse, CIC ¹⁴³⁶, Inserm, Université Paul Sabatier Toulouse III, Toulouse, France, Toulouse, France, ³Service de rhumatologie, Hôpitaux Universitaires de Strasbourg, INSERM UMR-S ¹¹⁰⁹, Strasbourg, France, Strasbourg, France, ⁴Horiana, Statistiques, Bordeaux, France, Bordeaux, France, ⁵Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS ¹¹³⁶-⁵, PARIS, France, Paris, France
Background/Purpose: A total of 98.8% of French citizens are registered in the National Health Data System (SNDS), which includes claims data of all reimbursed health-related…
Abstract Number: 0083 • ACR Convergence 2025
Confirmatory Factor Analysis of the Plutchik Suicide Risk Scale in Patients with Rheumatoid Arthritis
Pedro Quevedo¹, Javier mora², william garcia², alejandra Solano², juliana Muñoz² and Daniela Lopez², ¹San Rafael Cinic University Hospital, Bogota, Distrito Capital de Bogota, Colombia, ²san rafael clinic universtity hospital, Bogota, Distrito Capital de Bogota, Colombia
Background/Purpose: Prevalence of depression in RA patients ranging from 10% to 25%, making it the most common psychiatric disorder in this population. The Plutchik Suicide…
Abstract Number: 0062 • ACR Convergence 2025
Neddylation as a Therapeutic Target in Autoimmune Arthritis: Evidence from SKG Mice
Sho Sendo¹, Alfonso Del Peral Fanjul², Kazuma Nishisaka², Hirotaka Yamada¹, Takaichi Okano¹, Keisuke Nishimura¹, Yo Ueda¹ and Jun Saegusa², ¹Kobe University Hospital, Kobe, Japan, ²Kobe University, Kobe, Japan
Background/Purpose: Neddylation, NEDD8 conjugating process, is a post-translational modification that plays a crucial role in regulating ubiquitination by targeting cullin (CUL)-ring E3 ubiquitin ligases. Our…
Abstract Number: 2628 • ACR Convergence 2025
Calprotectin and Anti-CCP Antibodies Predict Development of Preeclampsia
Daniele Marcy¹, Nanette Santoro², Claudia Lugo³, Kristin Sturm² and Kristen Demoruelle⁴, ¹University of Colorado, Northglenn, CO, ²University of Colorado Anschutz Medical Campus, Aurora, CO, ³University of Colorado, Denver, CO, ⁴University of Colorado Anschutz Medical Campus, Golden, CO
Background/Purpose: Several systemic autoimmune diseases are associated with an increased risk of preeclampsia. Preeclampsia is a pregnancy complication characterized by new-onset hypertension after 20 weeks…
Abstract Number: 2289 • ACR Convergence 2025
Effects of Transcutaneous Auricular Vagus Nerve Stimulation on Disease Activity in Patients with Rheumatoid Arthritis: A Pilot Study
Yuichiro Fujieda¹, Kaoru Murakami², Hiroki Tanaka², Yuichi Kojima², Yuki Kudo¹, Kohei Karino¹, Hiroyuki Nakamura¹, Ryo Hisada¹, Michihito Kono¹, Masaaki Murakami² and Tatsuya Atsumi¹, ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan, ²Institute for Genetic Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
Background/Purpose: Vagus nerve stimulation (VNS) has emerged as a potential therapeutic strategy for inflammatory diseases by modulating inflammatory reflex pathways. Transcutaneous auricular vagus nerve stimulation…
Abstract Number: 2271 • ACR Convergence 2025
Assessing the Real-World Impact of Earlier Initiation of Adalimumab vs. Conventional Synthetic DMARDs on Healthcare Resource Utilization in Patients with Rheumatoid Arthritis in Europe
Daniel Aletaha¹, Dr. Carmen Bremer², Jack Milligan³, Zichun Cao⁴, Rachael Meadows³ and Xenofon Baraliakos⁵, ¹Medical University Vienna, Wien, Austria, ²Sandoz International GmbH, Holzkirchen, Germany, ³Adelphi Real World, Macclesfield, United Kingdom, ⁴Sandoz Incorporated, Princeton, ⁵Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Early use of targeted therapy (TT), such as anti-tumor necrosis factor (anti-TNF) biologics, show improved outcomes for RA1, but costs often limit access. Biosimilars,…
Abstract Number: 2255 • ACR Convergence 2025
Diagnostic Accuracy of Anti-Carbamylated Protein Antibodies in Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Pannathorn Nakaphan¹, Patavee Pajareya², Priabprat Jansem³, Somkiat Phutinart², Nattanicha Chaisrimaneepan⁴ and Noppachai Siranart², ¹Department of Internal Medicine, Weiss Memorial Hospital, Chicago, IL, ²Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, ³Department of Psychiatry, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand, ⁴Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX
Background/Purpose: Anti-carbamylated protein antibodies (anti-CarP Ab) are emerging serologic markers in rheumatoid arthritis (RA). Anti-CarP Ab has a controversial diagnostic utility in RA but may…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].